The vaccine and cervical cancer screen project 2 (VACCS 2): Linking cervical cancer screening to a two-dose HPV vaccination schedule in the South-West district of Tshwane, Gauteng, South Africa

South African Medical Journal

Volumn 105, Issue 3, 2015, Pages 191-194

  Snyman, L C ^a   Dreyer, G ^a   Visser, C ^a   Botha, M H ^b   van der Merwe, F H ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Cancer prevention; Linking; Papillomavirus

Indexed keywords

ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CANCER SCREENING; CAREGIVER; DNA EXTRACTION; HUMAN; IMMUNOGENICITY; PUBLIC HEALTH; QUESTIONNAIRE; SOUTH AFRICA; UTERINE CERVIX CANCER; VACCINE AND CERVICAL CANCER SCREEN PROJECT 2; WART VIRUS; ADULT; AGE; AGED; CHILD; COMPLICATION; EARLY DIAGNOSIS; FEASIBILITY STUDY; FEMALE; IMMUNIZATION; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRIMARY PREVENTION; PROCEDURES; SCHOOL; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIROLOGY; YOUNG ADULT;

WART VIRUS VACCINE;

ADULT; AGE FACTORS; AGED; CHILD; EARLY DETECTION OF CANCER; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRIMARY PREVENTION; SCHOOLS; SOUTH AFRICA; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84923767172     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.8888     Document Type: Article

References (17)

1. ICO (Institut Catala d’Oncologia) Information Centre on HPV and Cancer. South Africa. Human papillomavirus and related cancers, fact sheet 2013. http://www.hpvcentre.net/statistics/reports/ZAF_FS.pdf (accessed 17 April 2014)..
2. Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H. Part I: Cancer in indigenous Africans–burden, distribution, and trends. Lancet Oncol 2008;9(7):683-692. [http://dx.doi.org/10.1016/S1470-2045(08)70175-X].
3. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: Low average levels and large inequalities. PLoS Med 2008;5(6):e132. [http://dx.doi.org/10.1371/journal. pmed.0050132].
4. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006;367(9518):1247-1255. [http://dx.doi. org/10.1016/S0140-6736(06)68439-0].
5. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95(11):1459-1466. [http://dx.doi.org/10.1038/sj.bjc.6603469].
6. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial. JAMA 2013;309(17):1793-802. [http://dx.doi.org/10.1001/jama.2013.1625].
7. Romanowski B, Schwarz TF, Ferguson LM, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study. Hum Vaccine Immunother 2014;10(5):1155-1165. [http://dx.doi.org/10.4161/hv.28022].
8. Snyman LC, Dreyer G, Botha MH, van der Merwe, FH, Becker PJ. The Vaccine and Cervical Cancer Screen (VACCS) project: Linking cervical cancer screening to HPV vaccination in the South-West District of Tshwane, Gauteng, South Africa. S Afr Med J 2015;105(2):115-120. [http://dx.doi.org/10.7196/SAMJ.8418].
9. Heideman DA, Hesselink AT, Berkhof J, et al. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol 2011;49(11):3983-3985. [http://dx.doi.org/10.1128/JCM.05552-11].
10. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: A theory-informed, systematic review. Prev Med 2007;45(2-3):107-114. [http://dx.doi.org/10.1016/j.ypmed.2007.05.013].
11. Brotherton JM, Murray SL, Hall MA, et al. Human papillomavirus vaccine coverage among female Australian adolescents: Success of the school-based approach. Med J Aust 2013;199(9):614-617. [http://dx.doi.org/10.5694/mja13.10272].
12. Botha MH, van der Merwe FH, Snyman LS, Dreyer G. The Vaccine and Cervical Cancer Screen (VACCS) project: Acceptance of human papillomavirus vaccination in a school-based programme in two provinces of South Africa. S Afr Med J 2015;105(1):40-43. [http://dx.doi.org/10.7196/SAMJ.8419].
13. Moodley I, Mubaiwa V, Tathiah N, Denny L. High uptake of Gardasil vaccine among 9-12-year-old schoolgirls participating in an HPV vaccination demonstration project in KwaZulu-Natal Province. S Afr Med J 2013;103(5):318-321. [http://dx.doi. org/10.7196/SAMJ.6414].
14. Mnisi EF, Dreyer G, Richter KL, Horton A, Snyman LC. Human papillomavirus DNA testing on self-collected vaginal tampon samples as a cervical cancer screening test in a Gauteng population. S Afr J Gynaecol Oncol 2013;5(2):S15-S20..
15. Richter KL. Understanding and incorporating human papillomavirus testing in cervical cancer screening: A South African perspective. S Afr J Gynaecol Oncol 2011;3(1):9-14..
16. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26(Suppl 10):K29-K41. [http://dx.doi.org/10.1016/j. vaccine.2008.06.019].
17. Racey CS, Withrow DR, Gesink D. Self-collected HPV testing improves participation in cervical cancer screening: A systematic review and meta-analysis. Can J Pub Health 2013;104(2):e159-e166. [http://www.ncbi.nlm.nih.gov/pubmed/23618210].